April 1, 2020
PassPort Technologies, Inc.
Tokyo University of Science

PassPort Technologies and Tokyo University of Science Initiate Joint Research toDevelop Anticancer and Antiviral Therapeutics using Ridaifen
Expectations for early clinical application of revolutionary anticancer drugs from
Tokyo University of Science using a novel delivery technology
PassPort Technologies, Inc. (PPTI) has commenced joint research with the Research Institute for Science &Technology at Tokyo University of Science (Chemical Biology Division Supported by Practical Organic Synthesis),aiming to develop anticancer and antiviral drugs with a novel mechanism of action using a unique drug deliverytechnology.
PPTI is developing its proprietary PassPort® System to painlessly deliver drugs through the skin and efficiently
treat various diseases. In parallel, Professors Isamu Shiina and Motoyuki Shimonaka of Tokyo University ofScience, along with Professor Yukitoshi Nagahara of Tokyo Denki University (also currently a Visiting Professor atTokyo University of Science), have created a molecular compound, Ridaifen, that has a clear pharmaceuticaleffect. Ridaifens, a novel series of tamoxifen derivatives, have the ability to control the human immune systemand exert various biological activities through a novel mechanism that activates the function of scaffold proteins invivo (patent pending). Researchers at Tokyo University of Science have successfully conducted animal
experiments and observed tumor regression after direct injection of Ridaifen.
As part of the research collaboration between the organizations, a new anticancer drug targeting malignant
tumors will be combined with the PassPort® System to enable effective transdermal drug delivery. It is anticipatedthat wide range of pharmaceutical candidates, including antivirals (dengue virus, cytomegalovirus, influenza virus,
HIV, or hepatitis C virus, for example) and anti-infectives (antibacterial agents, for example), can also bedeveloped and evaluated.
This joint research is being carried out in Japan by Tokyo University of Science and Tokyo Denki University, withsupport from the Strategic Program for Bridging Research of the Japan Agency for Medical Research andDevelopment (AMED).

About the PassPort® SystemThe PassPort® System is a patent-protected innovative transdermal drug delivery platform developed exclusively
by PassPort Technologies, Inc. The system combines needle-free device technology that painlessly createsmicropores on the skin surface with patch formulation technology that controls drug absorption through themicropores. By using PassPort®, it is now possible for the systemic transdermal administration of drugs that havepreviously been limited to injections or infusions. Unlike conventional transdermal patches that are only applicableto low molecular weight drugs, PassPort® can also deliver other modalities such as medium molecular weightdrugs (including peptides and oligonucleotides) and macromolecular biopharmaceuticals (such as proteins).
About PassPort Technologies, Inc.
Located in San Diego, California, PassPort Technologies Inc. (PPTI) is focused on the development of advanced
drug delivery systems to create innovative pharmaceutical products. After being spun out of Nitto Denko
Corporation in July 2019, the company was established to continue R&D efforts towards the commercialization ofthe PassPort® transdermal platform. With strong technical knowledge and decades of experience in both
pharmaceutical sciences and engineering, the PPTI team possesses the necessary expertise in transdermal
formulations and medical device development that the PassPort® system requires. The company currently
collaborates with a wide range of partners that includes leading academic institutions, specialty biotechnology
groups, and multinational pharmaceutical companies. In addition to an active internal pipeline of encompassing
NCE, 505(b)(2) and BLA products, PPTI is also able to quickly formulate and evaluate partners’ drug, vaccine,and cosmetic candidates using the PassPort® system. For more information, please visit https://PassPortTech.com
About The Tokyo University of Science
Tokyo University of Science (TUS) is a well-known and respected university, and the largest science-specialized
private research university in Japan, with four campuses in central Tokyo and its suburbs and in Hokkaido.
Established in 1881, the university has continually contributed to Japan's development in science throughinculcating the love for science in researchers, technicians, and educators. With a mission of "Creating scienceand technology for the harmonious development of nature, human beings, and society", TUS has undertaken awide range of research from basic to applied science. TUS has embraced a multidisciplinary approach to researchand undertaken intensive study in some of today's most vital fields. TUS is a meritocracy where the best inscience is recognized and nurtured. It is the only private university in Japan that has produced a Nobel Prizewinner and the only private university in Asia to produce Nobel Prize winners within the natural sciences field. For
more information, please visit https://www.tus.ac.jp/en/

■ For inquiries, please contact:
PassPort Technologies, Inc.
Jared Hahn
Head of Business Development
10618 Science Center Drive, San Diego, CA 92121 USA
Phone: +1-858-888-4188
E-mail: info@passport-tech.com
URL: https://PassPort-Tech.com
Tokyo University of Science
Professor Isamu Shiina
Department of Applied Chemistry, Faculty of Science, Tokyo University of Science
1-3-2 Kagurazaka, Shinjuku-ku, Tokyo, 162-8601 Japan
Phone: +81-3-3260-1699
E-mail: shiina@rs.kagu.tus.ac.jp
URL: https://www.rs.kagu.tus.ac.jp/shiina/indexj.html